For UK MedTech companies
Your clinical evidence exists. Your marketing materials don't show it.
Feature-led brochures and outdated websites undermine the credibility of clinical champions at the moment it matters most, costing you competitive tenders that your evidence should win.
Two minutes. Solva follows up with specific evidence translation options.
HTWorld's 2024 MedTech marketing survey found that 65% of MedTech sales reps said their marketing materials did not adequately reflect the clinical evidence available, leading to lost credibility in procurement meetings.
Frequently asked questions
Why does this problem persist?
MedTech companies often invest heavily in clinical trials and publications but fail to translate this evidence into compelling sales and marketing materials. Brochures remain feature-led, websites are not updated with new data, and sales teams lack evidence-based talking points that match the language of clinical procurement.
What is the cost of leaving it unaddressed?
Outdated or evidence-light materials undermine clinical champion credibility and extend procurement timelines. Rebuilding evidence-led collateral typically increases win rates by 20–30% in competitive tenders. (HTWorld, 2024)
This is exactly what I do with UK private practices. Answer the few questions above and I'll come back personally with where to start. Paul.